Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VICTORION-2 PREVENT inclisiran cardiovascular outcomes trial
NL-OMON56097Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Mar 2022
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic disease and hypercholesterolemia comparing Inclisiran + high-intensity statin therapy with Placebo + high-intensity statin therapy (2 arms). Primary endpoint: Time to first 3-point major adverse cardiovascular event. Started Mar 2022; status: recruiting.
02
Drugs
inclisiran
03
Conditions
atherosclerotic diseasehypercholesterolemia
Beyond the preview
Go deeper on NL-OMON56097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56097.